US · Healthcare · Medical Devices
EPS came in at -0.08 against a street estimate of -0.15 — a beat of 46.7%.
Analysts rate Sight Sciences Inc a buy (5 buy, 2 hold, 0 sell out of 7) with an average price target of $9.40.
| Fund | Stake |
|---|---|
| Long Focus Capital Management, LLC | 6.98% |
| BlackRock Inc | 5.60% |
| Americana Partners, LLC | 3.05% |
| Pathstone Holdings LLC | 3.05% |
| Vanguard Capital Management, LLC | 2.86% |
| B Group, Inc | 1.76% |
| Geode Capital Management, LLC | 1.74% |
| State Street Corp | 1.52% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sight Sciences Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.